Checkpoint Therapeutics, Inc.
DelistedCIK 1651407fmd_0ABNVE7SFRFFQ934W90DC8VYSXManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Mar 31, 2025, 41 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | – | – | 0 | 0 | 0 |
| Research and development | 11 | 20 | 19 | 34 | 19 | 16 | 48 | 50 | 44 | 36 |
| Total operating expenses | 14 | 25 | 25 | 40 | 27 | 24 | 57 | 59 | 52 | 56 |
| Operating income | (13) | (22) | (23) | (37) | (25) | (23) | (57) | (58) | (52) | (56) |
| Interest expense | 0 | 0 | 0 | – | – | – | – | – | – | – |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income (expense) | (1) | (0) | 0 | 0 | 0 | 0 | 0 | (4) | 0 | (0) |
| Net income | (14) | (22) | (23) | (36) | (25) | (23) | (57) | (63) | (52) | (56) |